Petrilli et al. [85] evaluated the potential of EGFR targeted immuno-liposomes, composed of cetuximab encapsulated by 5-FU, against squamous cell carcinoma (SCC) in vitro using A431 (EGFR positive) and B16F10 (EGFR negative) cell lines, as well as in an in vivo animal model. Here, EGFR is linked to squamous cell carcinoma.